Abzena

Abzena is a biologics research partner providing integrated end-to-end solutions for the discovery, development and manufacturing of biopharmaceuticals. The company offers antibody and protein engineering, including humanization, deimmunization, affinity maturation and reformatting, as well as antibody drug conjugate design and conjugation technologies. It supplies discovery and development capabilities such as phage display, Hybridoma sequencing, developability and immunogenicity assessments, bespoke bioassays and analytics, and in vitro safety evaluations. Abzena also provides mammalian cell line development, process and analytical development, and manufacturing services for biopharmaceuticals, with capabilities spanning production, bioanalytics, and assay development. Its integrated ecosystem encompasses cell line platforms, rapid analytics, immunogenicity testing, and bioconjugation workflows to de-risk and accelerate drug development from discovery through mid-phase development and toward clinical readiness, serving biopharma and biotech clients with scientifically robust, regulatory-compliant solutions that aim to shorten time to clinic.

Antony Godwin

Founder

Peter Gray

Chairman

4 past transactions

The Chemistry Research Solution

Acquisition in 2015
The Chemistry Research Solution

PacificGMP (now Abzena)

Acquisition in 2015
PacificGMP Inc. is a contract manufacturing organization, engages in developing and manufacturing biologics. It produces monoclonal antibodies, recombinant proteins, vaccine products, insect cell/baculovirus, anchorage and suspension cells, and gene therapy products.

PolyTherics

Acquisition in 2013
PolyTherics has focused on technology development in the area of biomedical polymers for therapeutic applications. The most advanced of its techniques, site-specific PEGylation or TheraPEG, is being exploited in partnership with companies developing biopharmaceuticals. PolyTherics is also committed to developing its own pipeline of optimised clinical candidates.

Antitope

Acquisition in 2013
Antitope Ltd is a biotechnology research company, develops non-immunogenic protein therapeutics.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.